MALT Lymphoma Treatment
For gastric MALT lymphoma, H. pylori eradication therapy with PPI-based triple therapy (clarithromycin plus amoxicillin or metronidazole for 10-14 days) should be the sole initial treatment for all H. pylori-positive localized cases, regardless of stage, as this achieves complete remission in approximately 75% of patients. 1, 2
Treatment Algorithm by H. pylori Status and Stage
Localized Gastric MALT Lymphoma (Stage IE-IIE)
H. pylori-Positive Cases
- First-line: PPI + clarithromycin-based triple therapy (with amoxicillin or metronidazole) for 10-14 days 1
- Verification: Check eradication with urea breath test or stool antigen test at 6 weeks post-treatment (at least 2 weeks after stopping PPI) 1
- If eradication fails: Use second-line triple or quadruple therapy regimens 1
- Response timeline: Wait up to 12 months for complete remission, even with persistent histological lymphoma if clinical/endoscopic remission achieved 1
- Follow-up: Repeat endoscopy with biopsies at 3-6 months post-eradication 1
H. pylori-Negative Cases
- Consider trial of anti-Helicobacter therapy (occasional responses occur, possibly from false-negative tests or other Helicobacter species) 1
- If no response at 2-3 months: Proceed immediately to oncological treatment 1
- Preferred oncological treatment: Radiotherapy with 24-30 Gy to stomach and perigastric nodes over 3-4 weeks 1
Refractory to H. pylori Eradication
Treatment selection depends on specific features:
- Localized disease without high-risk features: Radiotherapy (24-30 Gy) 1
- Presence of t(11;18) translocation: Avoid alkylating agents as monotherapy; use radiotherapy or rituximab-based regimens 1
- Deep gastric wall invasion, nodal involvement, or symptomatic disease: Radiotherapy or systemic therapy 1
- Histological transformation: Chemoimmunotherapy mandatory 1
Advanced Gastric MALT Lymphoma (Stage IV)
All Patients
- If H. pylori-positive: Start with eradication therapy regardless of stage 1
Asymptomatic Disease
- Watch-and-wait approach with endoscopy/biopsies and imaging every 6 months 1
Symptomatic Disease or Treatment Indications
Indications for systemic treatment:
- Overt progression
- Bulky disease
- Impending organ damage
- Patient preference
Preferred regimen: Rituximab plus chemotherapy 1
- Rituximab + chlorambucil (proven efficacy in randomized study, though no overall survival benefit demonstrated) 1
- Alternative options: Rituximab + bendamustine, oral alkylating agents, or purine analogues 1
Critical Caveats and Pitfalls
Molecular Persistence
Monoclonal B-cells frequently persist after histological regression—this does not indicate treatment failure and does not require immediate intervention 1
Surgery Has No Role
Surgery impairs quality of life without superior outcomes compared to conservative approaches; it should not be used for initial treatment 1
Aggressive Chemotherapy
Anthracycline-containing regimens (like CHOP) are unnecessary for typical MALT lymphoma and should be reserved only for histological transformation to high-grade lymphoma 1
Purine Analogue Risk
Treatment with purine analogues (fludarabine, cladribine) carries increased risk of secondary myelodysplasia 1
Predictors of Poor Response to Eradication
- t(11;18) translocation
- Deep gastric wall invasion (beyond submucosa)
- Regional lymph node involvement
- Absence of H. pylori 1
Regional Antibiotic Resistance
In areas with clarithromycin resistance >15%, abandon classical triple therapy and use quadruple regimens with or without bismuth 4
Non-Gastric MALT Lymphoma
While the evidence focuses primarily on gastric MALT lymphoma, the ESMO guidelines 2 indicate that treatment approaches for non-gastric sites should be individualized based on anatomic location, with consideration for site-specific infectious triggers (e.g., Borrelia burgdorferi for cutaneous MALT, Chlamydia psittaci for ocular adnexal MALT).